Merck & Co., Inc. Reports Strong Sales Growth in Second-Quarter 2026 Financial Results

Merck & Co., Inc., Rahway, N.J., USA announced its second-quarter 2026 financial results, highlighting key regulatory and clinical milestones across its diverse pipeline. Chairman and CEO Robert M. Davis said the company made substantial progress this quarter, driven by strong execution and growing contributions from new product launches.

The FDA approval of LIPFENDRA marked a significant moment for Merck & Co., Inc. in cardiovascular disease, reflecting the strength of its pipeline and portfolio transformation as it brings forward the next wave of innovation. The company's financial results showed a 5% increase in sales to $16.607 billion, with GAAP net loss per share at $0.54 due to a charge for the acquisition of Terns Pharmaceuticals, Inc.

MERCK's top products drove growth, with KEYTRUDA/KEYTRUDA QLEX seeing a 5% increase in sales to $8.366 billion and GARDASIL/GARDASIL 9 reaching a 4% increase in sales to $1.169 billion. The company also reported strong performance from its Animal Health segment, with an 8% increase in sales to $1.775 billion.

However, some products saw declines, including JANUVIA/JANUMET and LAGEVRIO. Merck & Co., Inc.'s R&D expenses increased significantly to $9.741 billion due to a $5.7 billion charge for the acquisition of Terns and higher clinical development spending.